Astrana Health (ASTH) news
Recent news
Barclays raises target price to $53 from $50 for Astrana Health, Inc.
Barclays has raised its price target for Astrana Health, Inc. (NASDAQ: ASTH) to $53 from $50, maintaining an Overweight rating on the stock following the company’s Q2 2026 earnings report. The adjustment reflects the firm’s confidence in Astrana Health’s operational performance and strategic…
AInvest Wire · Aug 7, 2026Astrana Health Inc: expects FY 2026 total revenue in the range of $3,800 mln to $4,100 mln
Astrana Health, Inc. (NASDAQ: ASTH) has provided guidance for its total revenue in fiscal year 2026, projecting a range of $3,800 million to $4,100 million. This forecast reflects the company’s confidence in its growth trajectory and operational performance, driven by its physician-centric,…
AInvest Wire · Aug 6, 2026Astrana Health Inc outlook Q3 revenue USD 1,000-1,030 million
Astrana Health, Inc. (NASDAQ: ASTH) has provided updated guidance for its third quarter of 2026, projecting total revenue in the range of $1,000 to $1,030 million. This forecast aligns with the company’s broader 2026 annual guidance, which anticipates adjusted EBITDA between $250 and $280 million.…
AInvest Wire · Aug 6, 2026Astrana Health Inc: BTIG raises target price to $65 from $50
BTIG has raised its price target for Astrana Health Inc (ASTH) to $65 from $50, reflecting a more optimistic outlook on the company’s financial prospects. The adjustment indicates that the firm sees potential for improved performance, possibly driven by strategic initiatives or market conditions…
AInvest Wire · Jul 14, 2026Astrana Health strengthens leadership team to accelerate long-term growth
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.